Carlisle Companies Incorporated's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Carlisle Companies Incorporated's ROA in the second quarter of 2026?
Carlisle Companies Incorporated achieved a return on average assets (ROA) of 11.62 % in its second quarter of 2026, this is above CSL's average return on assets of 9.32%.
Carlisle Companies Incorporateds assets during the 12 months ending in the second quarter of 2026 are valued at $6 billion

ROA fell compared to the first quarter of 2026, despite the net income growth of 99.84% from the first quarter of 2026.

However, within the Healthcare sector 83 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 494, from total ROA ranking in the first quarter of 2026 at 543.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	12.96 %	9.88 %	7.67 %	-0.34 %	-17.97 %
Y / Y Net Income Change	-0.23 %	-10.89 %	-21.74 %	-12.32 %	-64.09 %
Net Income (TTM) in million	725	725	741	776	806
Return On Assets (TTM)	11.62 %	11.97 %	12.51 %	13.36 %	13.86 %
CSL's Total Ranking	# 494	# 543	# 425	# 389	# 228
Total Assets (TTM) in million	6,235	5,990	6,263	6,457	5,519
Seq. Total Assets Change	4.09 %	-4.36 %	-3 %	16.98 %	1.26 %
Seq. Net Income Change	99.84 %	0.24 %	-40.52 %	-16.26 %	78.51 %

CSL's 5 Years Annual ROA >> Back to CSL Management Effectiveness >> Compare CSL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 20
Sector	# 84
Overall	# 510

Return On Assets Statistics
High	Average	Low
20.64 %	9.32 %	5.31 %
(Mar 31 2025)		(Jun 30 2013)

News about Carlisle Companies Incorporated Return on Assets ROA

Carlisle Companies' CEO Chris Koch Joins Business Roundtable and Boosts ROA Performance, Consolidating Market Leadership

Carlisle Companies Incorporated (NYSE:CSL), a leading provider of innovative building products and solutions, proudly announced today that its Chair, President, and CEO, Chris Koch, has been appointed as a member of Business Roundtable. This esteemed association comprises more than 200 chief executive officers from America s foremost companies, representing their collective voice in Washington, DC since 1972.
Business Roundtable provides a platform for CEOs to work closely together, influencing policy decisions that shape the nation s business landscape and bolster economic growth. Chris Koch s appointment to this influential body signifies Carlisle Companies position as a key player within the industry and underlines its commitment to effective leadership in the business community. It also provides an opportunity for Carlisle Companies to contribute to the shaping of policies that impact their sector and drive innovation and growth.

Financial Statements
Carlisle Companies Incorporated's Assets	$ 6,235 million	CSL's Balance sheet
Carlisle Companies Incorporated's Income	$ 255 million	Quarterly CSL's Income Statement
CSL's Income by Division		See CSL's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	7.67 %	-19.38 %	-0.1 %	-0.34 %	23.53 %
Total Assets in million	6,263	5,817	7,215	7,222	7,247
Y / Y Net Income Change	-43.54 %	71.34 %	-17.14 %	119.11 %	31.74 %
Net Income in million	741	1,312	766	924	422
Annual Return On Assets	11.83 %	22.55 %	10.61 %	12.79 %	5.82 %

CSL's 5 Years Annual ROA >> Back to CSL Management Effectiveness >> Compare CSL ROA to its Competitors

Comment on CSL's ROA in the fiscal year ending 2025

In the fiscal year 2025 Carlisle Companies Incorporated's ROA decreased compared to previous year to 11.83 %, due to deterioration of net income -43.54 % to $740.70 million, from $1,311.80 million a year ago, as CSL's assets were $6,263.00 million.

More Return On Assets Ratios
CSL's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CSL's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CSL's Competitors
Subscribers only: Roa for Carlisle Companies Incorporated's Suppliers
Subscribers only: Return On Assets for CSL's Customers

You may also want to know
CSL's Roi	CSL's Inventory Turnover Ratio	CSL's Growth Rates	CSL's Dividend Comparisons
	CSL's Profitability Ratios	CSL's Asset Turnover Ratio	CSL's Dividend Growth
CSL's Roe	CSL's Valuation Ratios	CSL's Financial Strength Ratios	CSL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Meiragtx Holdings Plc	29.37 %
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %
Mettler toledo International Inc	24.86 %
Medpace Holdings Inc	24.84 %
Caredx Inc	24.81 %
Acadia Pharmaceuticals Inc	24.38 %
Eli Lilly And Company	21.97 %
Innoviva Inc	21.64 %
Vaxart Inc	20.85 %
Zevra Therapeutics Inc	20.39 %
Iradimed Corporation	20.36 %
Protalix Biotherapeutics inc	20.09 %
Pro dex Inc	19.87 %
Electromed Inc	19.39 %
United Therapeutics Corporation	17.98 %
Resmed Inc	17.80 %
Krystal Biotech Inc	17.65 %
Chemed Corporation	17.52 %
Zoetis Inc	17.19 %
Vertex Pharmaceuticals Inc	16.88 %
Halozyme Therapeutics Inc	16.55 %
Alnylam Pharmaceuticals Inc	15.76 %
Intuitive Surgical Inc	15.63 %
Healthcare Services Group Inc	15.21 %
Inspire Medical Systems inc	15.21 %
Dexcom Inc	14.87 %
Neurocrine Biosciences Inc	14.73 %
Entera Bio Ltd	14.60 %

Date modified: 2026-09-14T03:51:12+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.